[Featured Stock] Sinopex Rises on News of MOU for Export of Domestic Blood Filter

Sinopex is showing strong performance in the early trading session. This appears to be driven by investor sentiment following the opening of the first overseas export route for the company's main product, the artificial kidney blood filtration (dialysis) device.

As of 9:09 AM on the 20th, Sinopex is trading at 7,610 KRW, up 11.42% (780 KRW) compared to the previous day.

On this day, Sinopex announced that it had signed a memorandum of understanding (MOU) with Moroccan medical device specialist company 'PRIMEDIC' for the export of blood filtration devices, which acted as a positive factor for the stock price. This marks the company's first step into the global blood dialysis market, estimated to be worth 120 trillion KRW, and simultaneously positions it as an exporter of artificial kidney blood filtration devices, which had relied entirely on imports for the past 60 years.

Sinopex plans to supply PRIMEDIC with artificial kidney blood filtration devices worth 2.18 million USD (approximately 3.2 billion KRW) over a primary contract period of three years.

Previously, Sinopex successfully completed a patient-use clinical trial involving 50 blood dialysis patients at five major domestic hospitals. This was the first official clinical trial conducted with a domestically produced artificial kidney blood dialysis filter, marking 59 years since blood dialysis began in Korea.

This content was produced with the assistance of AI translation services.